A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-5817 Injection

NCT06934408 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

92

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity
Overweight

Interventions

DRUG: HRS-5817 Injection
DRUG: HRS-5817 Injection Placebo

Sponsor

Fujian Shengdi Pharmaceutical Co., Ltd.